BF-170

• Description :

  BF-170 is a selective tau fibril binding agent with an EC50 of 221 nM. It exhibits good blood-brain barrier permeability, and after intravenous injection in mice, the concentration in brain tissue reaches 9.1% ID/g within 2 minutes (with a brain clearance rate of 0.25% ID/g after 30 minutes) . BF-170 can be used as a probe for tau protein pathology imaging in Alzheimer's disease (AD) . It plays an important role in early-stage AD research and holds potential for imaging studies of tau-related neurodegenerative diseases[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H315-H318-H335

• Target :

  Tau Protein

• Related Pathways :

  Neuronal Signaling

• Field of Research :

  Neurological Disease

• Smiles :

  C1=CC=C2C(=C1)C=CC(=N2)C3=CC=C(C=C3)N

• Molecular Formula :

  C15H12N2

• Molecular Weight :

  220.27

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

• References & Citations :

  [1]Okamura N, et al. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci. 2005 Nov 23;25 (47) :10857-62.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [22191-97-5]